Methimazole (Tapazole) Patent History and Generic Timeline

Methimazole is a small-molecule thionamide drug that inhibits thyroid peroxidase (TPO), the enzyme responsible for iodinating and coupling tyrosine residues on thyroglobulin to produce thyroxine (T4) and triiodothyronine (T3). It is distinct from propylthiouracil (PTU), a related thionamide with an additional peripheral T4-to-T3 conversion-blocking effect, and from carbimazole, a prodrug used mainly in Europe and the UK that converts to methimazole after absorption. Methimazole does not destroy hormone already in circulation, so clinical improvement typically takes weeks rather than days as stored hormone depletes.

Methimazole (brand name Tapazole) was first approved by the FDA in 1950, decades before the Hatch-Waxman Act of 1984 created the modern Abbreviated New Drug Application (ANDA) pathway for generics. Its original patents expired long ago, and the FDA Orange Book lists no active patent or exclusivity period for Tapazole. Multiple AB-rated generic manufacturers have supplied methimazole tablets in the United States for years, and no shortage is listed in the FDA's drug shortage database as of this writing in 2026.

Is methimazole still under patent?

No. Methimazole (1-methyl-2-mercaptoimidazole) is a simple compound first developed in the 1940s, and its original composition-of-matter protection expired well before Hatch-Waxman existed. Checking the Orange Book directly is the most reliable way to confirm current patent and exclusivity status for Tapazole, since these listings can in principle change and this article's snapshot should not be treated as permanent.

King Pharmaceuticals originally marketed Tapazole. Pfizer acquired King Pharmaceuticals in 2010 and became the NDA holder for Tapazole as part of that transaction. By that point generic methimazole had already been available in the U.S. market for years. Specific figures on the acquisition price and on the current brand-versus-generic prescription split are not independently confirmed in this draft's sourcing and should be verified before being cited as fact.

Why hasn't a new patent blocked generic access?

A new composition-of-matter patent cannot be obtained for a compound that has been in the public domain for more than 70 years. A new formulation patent would require a genuinely novel delivery system, such as an extended-release version, a new route of administration, or a combination product, none of which exists for methimazole as of this writing. The commercial incentive is also weak: methimazole is a low-priced generic with a relatively small U.S. market compared with high-revenue brand drugs, which limits the financial case for the kind of secondary-patent or reformulation strategies ("evergreening") sometimes seen with blockbuster medications. This is a reasonable inference from the drug's age and market size rather than a documented finding specific to methimazole, and it should be read as plausible rather than proven.

Should you ever ask for brand-name Tapazole instead of generic?

For nearly all patients, no. AB-rated generic methimazole has demonstrated bioequivalence to brand-name Tapazole and can be substituted automatically at the pharmacy in all states unless the prescriber writes "dispense as written." There is no established clinical advantage to paying more for brand-name Tapazole when a bioequivalent generic is available.

There are a few narrow situations where a patient or prescriber might reasonably deviate from an automatic generic swap, and this is where a decision framework is more useful than a blanket recommendation.

Generic methimazole decision framework

The common thread: nearly every legitimate reason to deviate from routine generic substitution is a manufacturer-level or pharmacy-level issue, not a reason to seek the brand product. Cost is never a valid reason to prefer brand over generic methimazole.

How does methimazole compare with propylthiouracil (PTU)?

Both drugs are thionamides that inhibit TPO. PTU has an additional effect of blocking peripheral T4-to-T3 conversion, which is part of why it is preferred in thyroid storm and, by many clinical guidelines, in the first trimester of pregnancy. Outside those specific situations, methimazole is generally favored because it can be dosed once daily rather than two or three times daily, and because the FDA issued a safety communication restricting PTU use after reports linking it to a higher risk of serious liver injury than methimazole.

That FDA safety position has been described in agency safety communications, though a specific source page could not be verified for this draft. Reported rates of agranulocytosis with methimazole and PTU are often described in clinical literature as low and roughly comparable between the two drugs, and reported remission rates after a course of antithyroid therapy for Graves' disease are often cited in the range of roughly one in three to one in two patients. These figures come from the broader clinical and guideline literature on antithyroid drug therapy; exact numbers vary by study population and this draft could not independently verify a single precise figure, so any specific percentage should be confirmed against a current primary guideline (such as American Thyroid Association materials) before being presented to a patient as an exact statistic.

What does treatment and monitoring typically involve?

Clinical guidance in this area generally calls for baseline complete blood count and liver function testing before starting methimazole, and for patients to be counseled to report sore throat, fever, jaundice, or dark urine immediately, since agranulocytosis, though uncommon, is the most serious acute risk. A course of antithyroid therapy for Graves' disease is commonly described as lasting around 12 to 18 months, after which some patients relapse and are offered radioactive iodine ablation or thyroidectomy, while others continue long-term low-dose methimazole. Exact relapse rates and long-term safety figures depend on the source study and were not independently verified for this draft; a prescriber's current guideline reference is the appropriate place to confirm specific numbers for an individual patient discussion. None of this is a substitute for individualized dosing or monitoring decisions, which should be made with the prescribing clinician.

International availability

Methimazole is listed on the WHO Model List of Essential Medicines, reflecting its recognized role as an accessible treatment for hyperthyroidism globally. Patent protection on methimazole expired internationally decades ago as well. In the UK and much of Europe, carbimazole, the prodrug that converts to methimazole in the body, is more commonly prescribed than methimazole itself, and it is also off-patent and manufactured generically. Country-by-country prescribing patterns and exact conversion dosing should be confirmed against local prescribing information rather than assumed from general reference material.

What is established, what is plausible, and what is not established

Established: Methimazole's original patents have expired, the FDA Orange Book lists no active patent or exclusivity for Tapazole, multiple AB-rated generic manufacturers supply methimazole tablets, and the FDA has taken a documented safety position favoring methimazole over PTU outside specific clinical scenarios such as early pregnancy and thyroid storm.

Plausible but not independently confirmed in this draft: Specific cash price ranges for a 30-day supply, the exact percentage of U.S. prescriptions filled as brand versus generic, exact agranulocytosis and remission rate percentages, and the precise dollar figure for the Pfizer-King Pharmaceuticals acquisition. These are commonly repeated in secondary sources but should be confirmed against current primary data (a recent pharmacy price check, IQVIA or similar dispensing data, or the relevant guideline document) before being published as precise figures.

Not established: That any new patent, exclusivity period, or reformulation could realistically restrict generic methimazole access in the near term. Based on the compound's age and the absence of any known pending reformulation, this appears very unlikely, but "unlikely" is a judgment based on the current absence of any known pipeline activity, not a guarantee.